ArticleNanomedicine (London, England)2016
Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy.
Article in Nanomedicine (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Ultrasound-guided interstitial photothermal therapy generates improved treatment responses in a 9464D model of neuroblastoma.Bioengineering & translational medicine · 2025Article
- Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.International journal of nanomedicine · 2025Review
- Photothermal Prussian blue nanoparticles generate potent multi-targeted tumor-specific T cells as an adoptive cell therapy.Bioengineering & translational medicine · 2024Article
- Aspects of Antiviral Strategies Based on Different Phototherapy Approaches: Hit by the Light.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Thermal Dose of Photothermal Therapy Generates Differential Immunogenicity in Human Neuroblastoma Cells.Cancers · 2022Article
- [MnNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- The Design of Abnormal Microenvironment Responsive MRI Nanoprobe and Its Application.International journal of molecular sciences · 2021Review
- Chemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Tools.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors.Frontiers in immunology · 2021Review
- International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020Review
- CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma.Translational oncology · 2020Article
- Immunologically modified MnFeChemical engineering journal (Lausanne, Switzerland : 1996) · 2020Article
- Advanced biomaterials for cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
- Synergic effect of doxorubicin release and two-photon irradiation of MnRSC advances · 2020Article
- Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment.Theranostics · 2020Article
- Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma.Biomaterials science · 2019Article
- Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Delivering safer immunotherapies for cancer.Advanced drug delivery reviews · 2017Review
- Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimTo engineer a novel nanoimmunotherapy comprising Prussian blue nanoparticles (PBNPs) conjugated to antigen-specific cytotoxic T lymphocytes (CTL), which leverages PBNPs for their photothermal therapy (PTT) capabilities and Epstein-Barr virus (EBV) antigen-specific CTL for their ability to traffic to and destroy EBV antigen-expressing target cells. MATERIALS &
methodsPBNPs and CTL were independently biofunctionalized. Subsequently, PBNPs were conjugated onto CTL using avidin-biotin interactions. The resultant cell-nanoparticle construct (CTL:PBNPs) were analyzed for their physical, phenotypic and functional properties.
resultsBoth PBNPs and CTL maintained their intrinsic physical, phenotypic and functional properties within the CTL:PBNPs.
conclusionThis study highlights the potential of our CTL:PBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.